Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Florida: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 120 | 5,824 | 49% |
| 2020 | 94 | 5,273 | 52% |
| 2021 | 92 | 5,346 | 54% |
| 2022 | 94 | 5,726 | 56% |
| 2023 | 102 | 6,741 | 58% |
| 2024 | 120 | 7,940 | 60% |
| 2025 from claims | – | 8,670 7,957–9,173 | 61% |
| 2026 forecast | – | 9,445 8,310–10,899 | 61% |
| 2027 forecast | – | 10,247 8,760–12,212 | 61% |
| 2028 forecast | – | 11,117 9,276–13,612 | 62% |
| 2029 forecast | – | 12,059 9,849–15,123 | 62% |
| 2030 forecast | – | 13,079 10,478–16,760 | 63% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 29% of the cases CMS names in Florida; 56 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 24% inpatient hospital, 76% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~9,400 | ~2,100 | ~7,300 |
| 2027 · ~10,200 | ~2,200 | ~8,000 |
| 2028 · ~11,100 | ~2,400 | ~8,700 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 21% (24% in 2025), hospital outpatient about 79% (76% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 98 | 6,069+1.9%/yr | +1.9%/yr | 2.9 | 0% | 9,990 in 2030+8.7%/yr |
| Tennessee | 58 | 3,989+4.5%/yr | +4.5%/yr | 5.7 | 2% | 5,930 in 2030+6.8%/yr |
| North Carolina | 56 | 3,414+0.2%/yr | +0.2%/yr | 3.5 | 0% | 4,080 in 2030+3%/yr |
| Georgia | 43 | 2,875+5.7%/yr | +5.7%/yr | 3.4 | 0% | 5,590 in 2030+12%/yr |
| Virginia | 42 | 2,548+1.9%/yr | +1.9%/yr | 2.5 | 0% | 4,620 in 2030+10%/yr |
| Maryland | 33 | 2,509+4.4%/yr | +4.4%/yr | 2.9 | 1% | 3,560 in 2030+6%/yr |
| Kentucky | 40 | 2,343+2.3%/yr | +2.3%/yr | 5.2 | 0% | 4,370 in 2030+11%/yr |
| South Carolina | 29 | 1,874+3.7%/yr | +3.7%/yr | 2.8 | 0% | 3,150 in 2030+9%/yr |
| Mississippi | 20 | 1,240+1.2%/yr | +1.2%/yr | 3.3 | 0% | 1,510 in 2030+3.4%/yr |
| Louisiana | 18 | 1,193+5.7%/yr | +5.7%/yr | 3.0 | 0% | 2,510 in 2030+13%/yr |
| Arkansas | 16 | 1,036−1.8%/yr | −1.8%/yr | 2.8 | 0% | 1,540 in 2030+6.9%/yr |
| Alabama | 19 | 1,031+1.9%/yr | +1.9%/yr | 2.4 | 0% | 1,640 in 2030+8%/yr |
| Oklahoma | 14 | 974+2.6%/yr | +2.6%/yr | 2.0 | 0% | 2,260 in 2030+15%/yr |
| Delaware | 12 | 798+6.5%/yr | +6.5%/yr | 4.7 | 0% | 1,560 in 2030+12%/yr |
| District of Columbia | 7 | 762+4.4%/yr | +4.4%/yr | 12.2 | 0% | 1,250 in 2030+8.6%/yr |
| West Virginia | 4 | 478−5.3%/yr | −5.3%/yr | 2.3 | 0% | 670 in 2030+5.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 1,186 | 280,238−2.5%/yr | −2.5%/yr | 131.01.2× | 59% | 307,900 in 2030+1.6%/yr |
| ERCP & endoscopic ultrasound | 119 | 8,114−0.6%/yr | −0.6%/yr | 3.71.2× | 6% | 9,910 in 2030+3.4%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Florida · Every state · Compare with Texas
United Therapeutics leads with 34% of company spending on these surgeons in 2025, −9 pts on 2024.
In 2025, 24 companies reported engagement with Florida’s surgeons worth $756K in consulting, speaking, meals and travel tied to these products, about $6,303 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.